Jesús Carlos Presa Lorite

ORCID: 0000-0003-4899-908X · 1 paper in corpus

review 2025

Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review

Biomedicines ·doi:10.3390/biomedicines13081851

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in c…